経皮皮膚パッチの世界市場規模：製品タイプ別、用途別、地域別、予測

経皮皮膚パッチの市場規模と予測

経皮皮膚パッチ市場規模は、2024年に89億2,000万米ドルと評価され、2026～2032年にかけてCAGR 4.87%で成長し、2032年には113億3,000万米ドルに達すると予測されます。

経皮皮膚パッチは、皮膚を通して薬剤を分布させ、血流への全身吸収を可能にする新しいドラッグデリバリーデバイスです。これらのパッチは、バッキング、薬物リザーバーまたはマトリックス、粘着層の3つの層で構成されています。薬剤は規則的に放出され、胃腸管と初回通過代謝を回避して皮膚の層を通して吸収されます。

皮膚を通して薬物や治療物質を送達する汎用性と有効性から、さまざまな用途に有用であるとして、ますます人気が高まっています。主な用途のひとつは、糖尿病や高血圧などの慢性疾患の治療です。例えば、インスリンパッチは、糖尿病患者が針を刺すことなく血糖値を調節できるようにし、患者のコンプライアンスと快適性を高めます。

技術や材料科学の飛躍的進歩により、今後ますます普及すると予想されます。マイクロニードリングとマイクロニードルパッチの革新により、薬物の吸収率が向上し、通常は経皮投与が難しい生物製剤やワクチンなどのより大きな分子の送達が可能になります。

経皮皮膚パッチの世界市場力学

経皮皮膚パッチの世界市場を形成している主な市場力学は以下の通り：

主な市場促進要因

慢性疾患の有病率の上昇：糖尿病、高血圧、疼痛関連疾患などの慢性疾患の有病率の上昇は、経皮皮膚パッチ産業の主要な促進要因です。これらの疾患では長期にわたる投薬が必要となることが多く、経皮投与が有力な選択肢となっています。

ドラッグデリバリー技術の進歩：マイクロニードル、ナノテクノロジー、より優れた皮膚透過技術などの経皮投与法の革新により、皮膚パッチの有効性と適応性が大幅に改善されました。これらの開発により、従来の方法では投与が困難であった生物製剤や高分子を含む、より広範な薬物のデリバリーが可能になりました。

患者のコンプライアンスと利便性に対する需要の高まり：経皮パッチは、経口薬や注射に代わるユーザーフレンドリーな薬剤として人気が高まっており、患者のコンプライアンスを向上させています。パッチは使い方が簡単で、貼付時の痛みがなく、投与回数が少なくて済むため、患者の間で人気があります。

主な課題

限られた製剤適合性：すべての薬剤が経皮パッチとして適切に包装できるわけではありません。ある種の薬剤は、その分子サイズや特性により、表皮バリアを透過する能力が限られています。このため、経皮投与が可能な治療法の種類が制限され、その結果、経口剤や注射剤に比べて市場規模が小さくなります。

皮膚刺激とアレルギー反応：継続的なパッチの使用により、皮膚刺激、アレルギー反応、不快感を持つ患者もいます。このような副作用は、不快感により処方された治療レジメンに従うことを躊躇させるため、患者のコンプライアンス低下の一因となる可能性があります。製造業者は、患者の受容性を向上させるために、生体適合性と皮膚耐性の問題に常に対処しなければなりません。

製造と品質管理：経皮吸収パッチは、複雑な技術と強力な品質管理手段を用いて製造されます。製造条件にばらつきがあると、薬物送達率やパッチの機能にばらつきが生じる可能性があります。製造工程全体を通して一貫性を確保し、良好な品質を維持することは非常に重要ですが、特に高度な技術を持たない中小企業にとっては難しい課題です。

主要動向

技術の進歩：材料と製造技術の大幅な進歩により、経皮パッチの有効性と安全性が向上しています。例えばマイクロニードル技術は、皮膚にマイクロチャネルを形成することでより効率的な薬物送達を可能にし、その結果、吸収がより速くなります。さらに、薬剤投与や患者の服薬アドヒアランスをモニターするセンサーなどのスマート技術の利用が人気を集めています。

慢性疾患管理に対する需要の高まり：糖尿病、高血圧、疼痛管理問題などの慢性疾患の有病率の増加が経皮皮膚パッチの需要を押し上げています。これらのパッチは、経口薬に代わるシンプルで非侵襲的な代替手段を提供することで、患者のコンプライアンスと生活の質を向上させます。

患者中心のソリューション：個別化医療や患者中心のヘルスケアソリューションがますます重視されるようになっています。経皮吸収パッチは、投与量の変更や投与プロファイルの調整など、患者独自のニーズに合わせて製造されています。カスタマイズされたパッチは的確な緩和を提供できるため、このアプローチは特に疼痛管理において不可欠です。

目次

第1章 イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 市場概要

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 経皮皮膚パッチ市場：製品タイプ別

• 概要
• 単層粘着薬
• 多層粘着薬
• リザーバー
• 蒸気パッチ
• マトリックス

第6章 経皮皮膚パッチ市場：用途別

• 概要
• 神経疾患
• 疼痛管理
• ニコチン断薬
• 心血管疾患

第7章 経皮皮膚パッチ市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Teva Pharmaceuticals USA Inc.
• Novartis AG
• Teikoku Pharma USA Inc.
• Mylan Inc.
• 3M
• Luye Pharma Group
• Purdue Pharma Manufacturing LP
• Henan Lingrui Pharmaceutical Ltd
• Mundipharma

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Transdermal Skin Patches Market Size and Forecast

Transdermal Skin Patches Market size was valued at USD 8.92 Billion in 2024 and is projected to reach USD 11.33 Billion by 2032, growing at a CAGR of 4.87% from 2026 to 2032.

Transdermal skin patches are novel drug delivery devices that distribute medication through the skin allowing for systemic absorption into the bloodstream. These patches are made up of three layers: a backing, a drug reservoir or matrix, and an adhesive layer. The medicine is released in a regulated manner and absorbed through the skin's layers bypassing the gastrointestinal tract and first-pass metabolism.

They are becoming increasingly popular for their versatility and efficacy in delivering drugs and therapeutic substances through the skin making them useful in a variety of applications. One of its key applications is in the treatment of chronic illnesses such as diabetes and hypertension. For example, insulin patches let diabetic patients to regulate their blood sugar levels without the need for needles boosting patient compliance and comfort.

They are expected to become increasingly popular in the future due to technological and material science breakthroughs. Innovations in microneedling and microneedle patches may boost drug absorption rates enabling for the delivery of bigger molecules such as biologics and vaccinations which are generally difficult to administer transdermally.

Global Transdermal Skin Patches Market Dynamics

The key market dynamics that are shaping the global transdermal skin patches market include:

Key Market Drivers:

Rising Prevalence of Chronic Diseases: The rising prevalence of chronic diseases such as diabetes, hypertension, and pain-related disorders is a major driver of the transdermal skin patch industry. These illnesses frequently necessitate long-term medicine making transdermal administration a viable alternative.

Advancements in Drug Delivery Technologies: Innovations in transdermal delivery methods such as microneedles, nanotechnology, and better skin permeation techniques have considerably improved skin patch efficacy and adaptability. These developments allow for the delivery of a wider spectrum of drugs including biologics and bigger molecules that were previously difficult to administer using traditional methods.

Growing Demand for Patient Compliance and Convenience: Transdermal patches are becoming increasingly popular as a user-friendly alternative to oral drugs and injections, hence improving patient compliance. Patches are popular among patients because they are simple to use, painless to apply, and require less frequent administration.

Key Challenges:

Limited Drug Formulation Compatibility: Not all drugs can be adequately packaged as transdermal patches. Certain medications have limited capacity to permeate the epidermal barrier due to their molecular size and characteristics. This limits the variety of therapies that can be administered transdermally resulting in a smaller market scope than oral or injectable options.

Skin Irritation and Allergic Reactions: Some users may have skin irritation, allergic reactions, or discomfort as a result of continuous patch use. These side effects might contribute to lower patient compliance as discomfort may dissuade people from following their prescribed treatment regimens. Manufacturers must constantly address biocompatibility and skin tolerance issues in order to improve patient acceptance.

Manufacturing and Quality Control: Transdermal patches are manufactured using complicated techniques and strong quality control measures. Variations in manufacturing conditions can cause discrepancies in medication delivery rates and patch function. Ensuring consistency and maintaining good quality throughout the manufacturing process is critical but it can be difficult, particularly for smaller enterprises without advanced technologies.

Key Trends:

Technological Advancements: Significant advances in materials and manufacturing techniques are improving the efficacy and safety of transdermal patches. Microneedle technology, for example, enables more efficient medication delivery by forming micro-channels in the skin resulting in faster absorption. Furthermore, the use of smart technologies, such as sensors that monitor medicine administration and patient adherence, is gaining popularity.

Growing Demand for Chronic Disease Management: The increasing prevalence of chronic diseases such as diabetes, hypertension, and pain management problems is driving up demand for transdermal skin patches. These patches provide a simple, non-invasive alternative to oral drugs, thereby increasing patient compliance and quality of life.

Patient-Centric Solutions: There is an increasing emphasis on personalized medicine and patient-centered healthcare solutions. Transdermal patches are being produced to meet unique patient needs such as changing doses and adjustable delivery profiles. This approach is especially essential in pain management as customized patches can provide precise alleviation.

Global Transdermal Skin Patches Market Regional Analysis

Here is a more detailed regional analysis of the global transdermal skin patches market:

North America:

North America dominates the transdermal skin patches market with the United States taking the lead. This dominance stems mostly from the high frequency of chronic diseases, an aging population, and improved healthcare infrastructure. The increasing frequency of chronic diseases in North America is a major driver of the transdermal skin patch market. According to the Centers for Disease Control and Prevention (CDC), by 2021, 6 out of 10 adults in the United States will have a chronic disease, with 4 out of 10 having two or more. Diabetes affects around 37 million Americans (11.3% of the population), and it is commonly treated using transdermal patches.

The National Institutes of Health (NIH) invested USD 41.7 Billion in medical research in 2020, which could aid transdermal patch technology development. The United States Bureau of Labor Statistics predicts a 9% increase in medical scientist employment from 2020 to 2030, reflecting continuous research into drug delivery techniques. The United States Department of Health and Human Services predicted that national health expenditures would exceed USD 4.1 Trillion in 2020, or $12,530 per person, indicating the significant healthcare spending that supports sophisticated medication delivery technologies such as transdermal patches.

Asia Pacific:

The Asia Pacific region is projected to experience rapid growth in the transdermal skin patches market owing to the rapidly aging population and rising prevalence of chronic disorders. This fast expansion is being driven by the region's enormous customer base, improved healthcare infrastructure, and growing healthcare costs. The elderly population in Asia Pacific is a major driver of the transdermal skin patch market. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the region's elder population (aged 65 and more) is predicted to more than double, from 651 million in 2020 to around 1.3 billion by 2050.

Furthermore, the WHO reports that cardiovascular disorders account for 31% of all deaths in Southeast Asia, indicating a significant market for transdermal patches used in cardiovascular therapy. In China, the National Health Commission reported that 34% of individuals had chronic diseases in 2020, affecting 390 million people. This high incidence rate fuels the demand for novel medicine delivery technologies such as transdermal patches. Furthermore, healthcare spending in the region is increasing, with the World Bank reporting that current health expenditure per capita in East Asia and Pacific increased by 62.5% from $571 in 2010 to $928 in 2019, indicating increased investment in healthcare technologies such as transdermal patches.

Global Transdermal Skin Patches Market: Segmentation Analysis

The Global Transdermal Skin Patches Market is segmented based on Product Type, Application, and Geography.

Transdermal Skin Patches Market, By Product Type

• Single-layer Drug-in-Adhesive
• Multi-layer Drug-in-Adhesive
• Reservoir
• Vapor Patch
• Matrix

Based on the Product Type, the Global Transdermal Skin Patches Market is a bifurcated into Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Reservoir, Vapor Patch, and Matrix. In the global transplant diagnostics market, multi-layer drug-in-adhesive products are anticipated to be the dominant segment. This dominance stems from their ability to provide sustained drug release which is critical in transplant procedures requiring precise medication management. Multi-layer systems allow for the controlled delivery of immunosuppressive drugs reducing the risk of rejection while minimizing side effects. Their enhanced efficacy and flexibility in formulation make them suitable for various applications in transplant diagnostics.

Transdermal Skin Patches Market, By Application

• Neurologic Conditions
• Pain Management
• Nicotine Cessation
• Cardiovascular

Based on the Application, the Global Transdermal Skin Patches Market is bifurcated into Neurologic Conditions, Pain Management, Nicotine Cessation, and Cardiovascular. In the global transdermal skin patches market, pain management is the dominant application segment. This dominance is attributed to the increasing prevalence of chronic pain conditions such as arthritis and back pain which significantly impacts the quality of life for many individuals. Transdermal patches offer a convenient, non-invasive method for delivering analgesics directly into the bloodstream ensuring steady medication levels and reducing the risk of side effects associated with oral medications. Additionally, the growing trend toward personalized medicine and patient-centric treatment options further enhances the appeal of pain management patches.

Transdermal Skin Patches Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Transdermal Skin Patches Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The North American region dominates the global transdermal skin patches market accounting for a significant share due to several key factors. Firstly, the region boasts advanced healthcare infrastructure leading to higher adoption rates of innovative drug delivery systems. The presence of major pharmaceutical companies and ongoing research and development initiatives further drive market growth. Additionally, a growing prevalence of chronic diseases such as diabetes and hypertension increases the demand for convenient drug delivery options.

Key Players

The "Global Transdermal Skin Patches Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Teva Pharmaceuticals USA, Inc., Novartis AG, Teikoku Pharma USA Inc., Mylan, Inc., 3M, Luye Pharma Group, Purdue Pharma Manufacturing LP, Henan Lingrui Pharmaceutical Ltd, and Mundipharma.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Transdermal Skin Patches Market Key Developments

• In September 2023, Corium, LLC, a biopharmaceutical company, revealed data proving the effectiveness of its donepezil transdermal system, ADLARITY, in a placebo-controlled trial of healthy volunteers. It is the first donepezil transdermal system authorized by the FDA in the United States for the treatment of mild, moderate, and severe Alzheimer's dementia.
• In September 2023, Zydus Lifesciences Ltd announced that it had received final FDA approval for its Norelgestromin and Ethinyl Estradiol Transdermal System. This skin patch distributes a combined hormone medicine that effectively prevents pregnancy.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL TRANSDERMAL SKIN PATCHES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL TRANSDERMAL SKIN PATCHES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL TRANSDERMAL SKIN PATCHES MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Single-layer Drug-in-Adhesive
• 5.3 Multi-layer Drug-in-Adhesive
• 5.4 Reservoir
• 5.5 Vapour Patch
• 5.6 Matrix

6 GLOBAL TRANSDERMAL SKIN PATCHES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Neurologic Conditions
• 6.3 Pain Management
• 6.4 Nicotine Cessation
• 6.5 Cardiovascular

7 GLOBAL TRANSDERMAL SKIN PATCHES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL TRANSDERMAL SKIN PATCHES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Teva Pharmaceuticals USA Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Novartis AG
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Teikoku Pharma USA Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Mylan Inc.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 3M
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Luye Pharma Group
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Purdue Pharma Manufacturing LP
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Henan Lingrui Pharmaceutical Ltd
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Mundipharma
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research